Aprotinin is a protease inhibitor isolated from bovine lungs and othcr lissues. Its biochcmical struc!Urc, a single-c hain polypeptide of 6.5 12 kD , and biophysical properties are weH defined. I The activity of commcrcial preparations of apralini n is usually describcd in kallikrein inac ti valor unils (KIU) , 0. 1 million KIU being equivalent 102. 15 j-Lmol of apralinin per liter. Sy inhibiting tryps in , plasmin , plasma kallikrein , and ti ssue kallikreins in addition 10 othcr serine proteases, aprol in in can affeel the fibrinolytic and coagu lation, compleme nt , and olher biologie systems. I Apralinin has Ileen shown 10 reduce blood product requiremenls significantly in cardiac surgery in a welldesigned randomized double-blind ITial.
able venous collaterals and, somelimes, multiple adhesions because of prcvious hepatobiliary or portal decompressive surgery. In addition, hyperfibrinolysis is espccially pronounced in the late anhepatic phase and immed iately after revascularization of the cold-slored graft , as has bcen shown by a number of studies . S--7 Thc Pittsburgh liver transplant group has shown that the degree of blood usage during ortholOpic li ver transplantation (OLT) correlates significantl y with postoperative mortality during the first half year after the procedure . 8 Excessive blood loss may lead to prolonged intubation and ventilation , impainnent ofrenal func tion , and an incrcased risk of infcc tion. Preventing excessive blood loss during li ver transplanlation may thus contribute to improveme nts of the overall results. Because hypcrfibrinolysis plays a significant role in liver transplantation , and bccause aprotinin acts as an antifibrinolytic agent, the potential role of aprotinin in liver transplantation has been in vestigatcd .
CLiNICAL STUDIES OF APROTININ IN LlVER TRANSPLANTATION
In the initial rcport of a potentially beneficial effect of aprotinin in li ver transplantation ,9 the agent was givcn only as a bolus of 0.5 million KIU during induction of anesthesia , immediately prior to the anhepatic phase, and immediately prior to reperfus ion. This low-dose bolus regimen was givcn instead of the continuous infusion promoted by the cardiac surgery study of Royston el al 2 because offear of a higher ri sk of subseq uenl Ihromboses of vascular anastomoses in the setting of liver transplantation without intraoperati ve anticoagulation. In the initial study of 10 consecutive primary allografts and 10 previous historie co ntrols, a significant reduction of blood product requireme nls followin g reperfusion of Ihe graft and a significanll y shorter operating lime from Ihe lime of reperfusion unlil skin closure were noted. 9 AddilionalJ y. the operative fi eld was often observed to be "bone dry" at the end of Ihe procedure , unlike the previously common diffuse oozing from previously dry surfaces. Such an unusually dry surgical fi eld had also been reported by cardiac surgeons using aprolinin , although dry ness is an admilledly subjecti ve assessment and difficult to quanlify. The resulls of our initial report were confinned by the group of RoUes at the Royal Free Hospital , London . England. [10] [11] [12] However, those workers applied aprotinin according 10 the dosage prolocol established by Royston 2 and associales with Ihe modification of adding 0.07 million KIU of aprotinin 10 each unit of blood Iransfu sed intraoperatively (Table I ). In this relrospeclive study with hislorical controls, the invesligators found . besides significant reductions in total transfu sion requiremenls, especially in the poslanhepatic stage, and a shortening of the operative time in patienls receiving aprolinin , a significant reduction of the mean lenglh of the ICU stay and thus concluded that aprotinin treatment implied overall reduction of the costs of liver transplantation.
Because of Ihese initial experiences with aprotinin, our group fe it Ihat a properly randomized placebo-controllcd trial would submit the patients in the control group to an unjustified risk , and we Iherefore continued to use aprotinin with careful prospeclive monitoring for eventual side effecls and concomitant analysis of parameters of the coagulation and fibrinolysis systems. Orthotopic liver transplantalion was carried out according to estab- With each unit of RBC , one unit of fre sh frozen plasma (FFP) was usually administered except in patients with severe ascites, who received additional units of FFP 10 compensale for Iheir massive protein loss. Whole blood , fresh whole blood, or platelets were not given. The Cell Saver for autologous blood transfu sion or a rapid infusion pump were never used. \3 In 46 conseculive patients receiving primary Ijver graft s according to Ihis protocol, and with bolus adminisIration of aprotinin (see above), the mean transfusion rcquircme nts were 7.5 ± 4.6 units of RBC and 9. I ± 6.7 units of FFP. These reductions of homologous blood product requirements were not stalistically significantly differenl from that of the initial historical control grou p (9 .7 ± 5.5 units of RBC and 10.4 ± 6.2 units of FFP). However, our expcrience compared very favorably with previous reports on blood product usage in OlT ( Table 2 ) .8.14-16 Furthennore , in 10 patients who received aprotinin , detailed analyscs of the coagulalion and fibrin olysis system were carried out. 7 Aprotinin did not prevent Ihe increase of tissue plasminogen aclivalor (1-PA) acti vity during the anhepalic phase, bUI the maximal values oft-PA aCli vily were lower than those reported by other investigators who did nol use aprot inin intraoperati ve l y .~ Using thc aprolinin dosage recommended by Royston and associales 2 (Table I) , Grossc el al 17 T eponed a 50% reduction of mean homologous blood praduct requiremcnts in a prospeclive study of25 consecutive pat ienls compared wilh 25 historica l controls. The I-PA aClivity levels werc significantly lower at thc time of repcrfusion of the graft than in the COn!rol grou p (see also the article by Grossc et al in this issue).
Because other invesligators had not observed higher risk of thrombosis al vascular anaslomoses using highdose aprotinin as in cardiac surgery . we carried out a Because olher invesligalors had nOI observed higher risk of thrombosis at vascu lar anasl0n10SeS using highdose aprotinin as in cardiac surgery. we carried out a randomized conl rolled trial compari ng our aprOlinin bolus regimen (n = 13; Group I) with a conrin uous intravenous infus ion prolocot (n = 10: Group 2) (Tabte 3).'8 Wirh conti nuous infusion, constanrly and significant ty higher syslemic aprotinin concentrat;ons could bc obrained evcn during rhe preanhepatic phase and throughout rhe enri re procedure compared with bolus applicarion (Fig . I ). There was a trend roward lower transfusion requ iremenrs in Group 2: however, it reached slaristicat significance fo r RBC usage only wirhi n Ihe fi rst 3 postoperative days (Table 4) . Ni ne of the patienrs in Group 2 showed no signs of hyperfibrino lys is as defincd by readings fro m the rhrombelastogram, and only one patient developcd severe hypcrfibri nolysi s. In comparison, 3 (Table 5 ) . In contrast to these results. Ihe on ly placebo-controlled. randomized srudy of aprorin in in liver tmnsplanlarion wilh a dosing scheme according 10 Royston lmd associates, 2 carried out by the Munich group, cou ld nol confirm a beneficial effcci of aprolinin with regard to blood product requirernenrs or orher of rhe aforementioned criteria. I <) The aprot in in group necded 18 un its of RBC, whereas the control group necded 20 units (NS).
The various aproti nin dosage schemes ernployed during OL T and publ ished 10 dare lire summarized above in Table I . More mcaningful may be a comparison or the 10lal estimaled aprot inin dose used intraopcrat ivety by various in vesli gators togelher wilh the mean transfusion rcqui remenrs (Table 6) ., WBL T -who le blood elot lysis time as measured by thrombe lastQgram.
transfusion requirements of 18 units of RBC. These differences are difficult to explain other than by speculating that on the one hand . the rnet iculous blood component therapy employed by the Munich group, which varies from the practice of most other transplant centers,20 counteracted potential effects of aprotinin, and that on the other hand, differences in the select ion and perioperalive management of the patients led to greater transfusion requirements.
POSSIBLE MECHANISMS OF ACTION OF APROTININ ON HEMOSTASIS DURING OLT
Thorough investigations of hemostasis in our patients suggest thai aprotinin bolus Ihera py led to smaJler t Hi storica l oon trols.
* Randomized placebo·co ntrolled study. § Randomized study of bol us vs COnli nuous infus ion of aprotinin (me· di an va lues). increases of profibrinolylic parameters than in the experience of other groupS.7 In a randomized controlled study of four patients in each group , comparing standard treatment wilh aprolinin infusion according 10 the Royslon protocol, Couam el a1 2 1.22 showed that I-PA levels were significantly lower in the aproti nin-treated patients at the end of the anhepatic phase . a fi nding similar to that observed in Ihe slUdy of Grosse el al t7 (see above) . FurIhennore, Cotlam and assoc iates reponed significantly higher levels of Q.2-anliplasmin during all stages of li ver transplantation following admini stration of aprotinin . They therefore hypothesized that aprotinin reduces t-PA produclion by inh ibi ting katlikrein and that aprotinin's known antiplasmin effec i might neutralize plasmin fonned by t-PA or kallikrein. 2 t . 22 The antifibrinolytic effect of aprotinin has also been demonstrated in an in vitro study by treati ng blood sampies oblained during O L T with aprotin in before perfonning IhromboeJastography. 23 The graft itsclf may play an imporlant role in the developrnent of hyperfibrinolysis after reperfusion. This has heen evident clinically through the obscrvation that oozing becomes apparent exclusively after revascu larization and has to be expected especiall y when using grafts with scvere ischemic damage or primary nonfunction. Besides monitoring the systemic levels of coagulation and fi brinolysis faclOrs, we wondered whether the graft itself might release activators of fibrinolysis. Therefore, blood passing through the li ver immediately after reperfusion and collected by venting the inferior vena cava was collected and analyzed. t8.24 In the previously mentioned randomized cornparison of 13 patients receiving aprotinin bolus therapy with 10 patients receiving continuous aprotinin infu sion, t-PA antigen and acti vity were lower. whereas PAT and Q.2-antiplasmin activities were higher in the perfusate collected from patients of the infusion group ( Table 7) . These resulls may be explained by the hypothesis Ihat higher aprot inin levels will reduce endothelial damage in the liver graft during reperfusion.
Lie cl al 25 first descri bed a proteclive effeci of aprotinin agaiost isehernic hepatocellular damage both in models ofwann hepa!ic isehern ia induccd by clamping of the hcpatoduodenal ligament in nonnal aod cirrhotic rats aod in cold isehern ia in a model of OlT in rats by pretrcating the livcr donors with aprotin iß. However. the results could not be confirmed in the isolated perfused rat li ver modcl. " u, On the olhcr hand, a large-animal study involving OLT in pigs dcmonstrated that treating the recipicms wilh a conlinuQus intravenous infusion of aprotinin resulted both in significantly less hepatocelJular isehernic damage , as renecled by postoperative serum levels of markers of liver cell integrity (SGOT), and significantly prolonged survival in comparison to eontrols. 27 These lauer swdies underseore a polential role of aprolinin in the prevenlion of repcrfusion injury ralher Ihan effecis during cold Siorage. as only Ihe live r reeipienls were Irealed.
ADVERSE EFFECTS OF APROTININ
Because aprolin in is of bov ine origi n, anaphylacloid reaclions may be obscrved, as with any olher foreign prolein. espccially during repcated exposure afler potenlial antibody format ion. Although we have never encounlered such reaclions in more Ihan 300 li ver transplanlations using aprolinin, not even after repeated administration (e.g . , in the setting of retransplantation of the liver), severe anaphylactoid reaelions have been reportcd . In a swdy involving more than 150 patients undergoing cardiae surgery, one single ease of severe hypotension Ihoughtlo be attributable to aprotin in has been reported . 4 Recently, such anaphylaet ic reae tions were shown 10 be IgF medialed. 28 lt Iherefore scems advi sable to obtain a medieal history of possible previous aprotinin exposure before treatme nt and to be prepared for appropriate management of any anaphylaeloid reaellons. Antihistamine reeeptor drugs can be adminisle red during induetion of anesthesia and before aprolin in adm inistrdlion ; inlraoperative use of steroids is part of the protoeol in most Iransplant centers and would also counterael anaphylaetoid reaetions.
CONClUSION
A number of clinieal stud ies have now shown a reduelion of blood produel requirements and deereased te ndenc ies for fibrinolysis , especialJ y during Ihe anhepatk and early reperfusion phase ofOLT, whe n aprotinin is administered intraopcrativcly. However, a large random ized trial with suffieient numbers of patienls and , preferably, a multicenterdesign is st ililaeking 10 confiml the protective effecls of aprotinin and the optimal dose beyond any doubL
